Table of Contents Table of Contents
Previous Page  101 / 110 Next Page
Information
Show Menu
Previous Page 101 / 110 Next Page
Page Background

251

Tabaco y peso corporal

S. Does combination pharmacological intervention for

smoking cessation prevent post-cessation weight gain?

A systemic review. Addictive Behaviors 2013; 38: 1865-

75.

2.- Strong DR, David SP, Johnstone EC, Ave-

yard P, Murphy MF, Munato MR. Differential

Efficacy of Nicotine Replacement Among Overweight

and Obese Women Smokers. Nicotine Tob Res 2015;

17: 855-61.

3.-

Bush T, Levine MD, Magnusson B, Cheng

Y, Chen X, Mahoney L, et al

. Impact of Baseline

Weight on Smoking Cessation and Weight Gain in Quit-

lines.

Ann Behav Med 2014; 47: 208-17.

4.- Ben Taleb Z, Ward KD, Asfar T, Jaber R,

Bahelah R, Maziak W. Smoking Cessation and

Changes in Body Mass Index: Findings From the First

Randomized Cessation Trial in a Low-Income Coun-

try Setting. Nicotine Tob Res. 2017 ;19:351-6. doi:

10.1093/ntr/ntw223.

5.- Farley AC, Hajek P, Lycett D, Aveyard

P.

Interventions for preventing weight gain alter

smoking cessation (Review). Cochrane Database of

Systematic Reviews 2012, Jan 8;1:CD006219. doi:

10.1002/14651858.

6.- Bush T, Levine MD, Beebe LA, Cerutti B,

Deprey M, McAfee T, et al. Addressing Weight

Gain in Smoking Cessation Treatment: A Randomized

Controlled Trial. Am J Health Promot 2012; 27: 94-102.

7.- Anderson J, Greenway F, Fujioka K, et

Gadde KM, McKenney J, O’Neil PM. Bupro-

pion SR enhances weight loss: A 48-week double-blind,

placebo-controlled trial. Obes Res 2002; 10: 633-41.

8.- Beard E, Shahab L, Cummings DM, Michie

S, West R. New Pharmacological Agents to aid Smok-

ing Cessation and tobacco Harm Reduction: What Has

Been Investigated, and What Is in the Pipeline? CNS

Drugs 2016; 30: 951-83.

9.- Levin ED, Johnson JE, Slade S, Wellis

C, Cauley M, Petro A, et al. A 5-HT2C agonist,

decreases nicotine self-administration in female rats. J

Pharmacol Exp Ther 2011; 338: 890-6.

10.- Greenway FL, Shanahan W, Fain R, Ma T,

Rubino D. Safety and tolerability review of lorcaserin

in clinical trials. Clin Obes 2016; 6: 285-95.

11.- Panakova A, Kralikova E, Kavalkova P,

Stepankova L, Zvolska K, Haluzik M. No

change in serum incretins levels but rise of leptin levels

after smoking cessation: a pilot study. Physiol Res 2016;

65: 651-9.

12.- Pi-Sunyer X, Astrup A, Fujioka K, Green-

way F, Halpem A, Rempf M, et al. A Random-

ized, Controlled Trial of 3.0 mg of Liraglutide in weight

management. N Engl J Med 2015; 373: 11-22.

13.- Kang JG, Park CY, Kang JH, Park YW, Park

SW. Randomized controlled trial to investigate the ef-

fects of a newly developed formulation of phentermine

diffuse-controlled release for obesity. Diabetes Obes

Metab 2010; 12: 876-82.

Correspondencia a:

Dra. María José Escaffi F.

Email: mescaff

i@c

lc.cl

Rev Chil Enferm Respir 2017; 33: 249-251